Insider transactions

NOVARTIS AG

CIK 1114448 · last filed 2020-07-16

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$1.31B
Companies
14
Total Filings
46
Lifetime Open-Market Net
$7.62M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

NTLA price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
LICHTSTRASSE 35
BASEL, V8 CH 4056
Phone
01141613241111
State of Incorporation
Switzerland
Related Filers
Novartis Bioventures Ltd — 85 joint filings, latest 2020-07-02
NOVARTIS PHARMA AG — 33 joint filings, latest 2022-06-27
ALNYLAM PHARMACEUTICALS, INC. — 11 joint filings, latest 2014-02-12
Novartis Institutes for BioMedical Research, Inc. — 10 joint filings, latest 2019-02-14
Carulla Victor Bulto — 2 joint filings, latest 2026-04-30
BlackRock Inc. — 1 joint filings, latest 2024-02-02
EastBridge Investment Group Corp — 1 joint filings, latest 2020-08-14
IONIS PHARMACEUTICALS INC — 1 joint filings, latest 2001-08-30
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Poseida Therapeutics, Inc. (PSTX) Delisted 10%+ Owner 5,908,089 $9.50 $56.13M $0 1 2020-07-16
Akouos, Inc. (AKUS) Delisted 856,262 $13.29 $11.38M $4.25M 1 2020-07-02
Galera Therapeutics, Inc. (GRTX) Delisted 10%+ Owner 17,448 $17.60 $307.1K -$729.4K 2 2020-06-12
Whitehawk Therapeutics, Inc. (ARPO) Delisted 10%+ Owner 346,207 $33.00 $11.42M -$695.9K 2 2019-04-05
Rein Therapeutics, Inc. (ALRN) Delisted 10%+ Owner 121,739 $2.11 $256.9K $7.47M 6 2018-08-16
ALT 10%+ Owner 186,579 $2.23 $416.1K $0 4 2018-06-15
NTLA 10%+ Owner 4,129,903 $11.65 $48.11M -$45.74M 3 2017-12-14
Ra Pharmaceuticals, Inc. (RARX) Delisted 10%+ Owner 2,307,877 — — $781.6K 4 2017-06-12
Spyre Therapeutics, Inc. (AGLE) Delisted 10%+ Owner 92,437 $12.01 $1.11M $6.00M 1 2016-04-12
KINETA, INC./DE (PTI) Delisted 10%+ Owner 74,940 — — $6.00M 1 2016-02-17
Eledon Pharmaceuticals, Inc. (TKAI) Delisted 10%+ Owner 502,765 — — $5.56M 5 2015-07-15
IDENIX PHARMACEUTICALS INC (IDIX) Delisted 33,185,191 — — $10.23M 9 2011-04-13
Adhera Therapeutics, Inc. (MRNAD) Delisted 10%+ Owner 2,804,670 — — -$619.8K 3 2011-01-25
ALNY 10%+ Owner 5,602,898 $225.10 $1.26B $15.11M 3 2010-04-26

Recent Filings · Page 3 of 5

46 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2017-03-07 NTLA Other (J) +158,490 $0 EDGAR
2016-10-31 Ra Pharmaceuticals, Inc. (RARX) Delisted Mixed +5,091,304 $2.20M EDGAR
2016-05-11 NTLA Mixed +11,147,316 $10.00M EDGAR
2016-04-12 Spyre Therapeutics, Inc. (AGLE) Delisted Mixed +4,621,848 $6.00M EDGAR
2016-02-17 KINETA, INC./DE (PTI) Delisted Mixed +3,747,582 $6.00M EDGAR
2015-07-15 Eledon Pharmaceuticals, Inc. (TKAI) Delisted Sell (S) −96,944 -$1.39M EDGAR
2015-06-16 Eledon Pharmaceuticals, Inc. (TKAI) Delisted Sell (S) −41,392 -$587.8K EDGAR
2015-06-12 Eledon Pharmaceuticals, Inc. (TKAI) Delisted Sell (S) −55,750 -$791.6K EDGAR
2015-03-20 Eledon Pharmaceuticals, Inc. (TKAI) Delisted Sell (S) −98,282 -$1.43M EDGAR
2014-09-24 Eledon Pharmaceuticals, Inc. (TKAI) Delisted Mixed +9,288,656 $9.75M EDGAR
Showing 21–30 of 46
Page 3 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.